Is there Co-infection of Influenza and Covid-19 in Jos, North Central Nigeria?
Main Article Content
Keywords
Coinfection, SARS-CoV-2, Influenza, Human, Nigeria, Epidemics
Abstract
Background: Influenza virus and severe acute respiratory syndrome virus-2 (SARS CoV-2) are known to cause respiratory disease in humans that may be fatal. They have caused epidemics and constitute significant public health challenges because of their ability to spread and cause severe disease. Co-infection with both viruses has been shown to increase the odds of fatality among affected patients. Our study aimed to investigate co-infection with influenza among patients with coronavirus disease-2019 (COVID-19) in Jos, Plateau State.
Methodology: We carried out a cross-sectional study using stored nasopharyngeal and oropharyngeal samples of patients diagnosed with COVID-19 using GeneXpert. The samples were collected at our institution and stored at −80 °C. The samples were analysed for influenza co-infection using real-time reverse transcriptase polymerase chain reaction.
Results: Two-hundred-and-forty-one (241) stored samples of patients diagnosed with COVID-19 were analysed. None of the samples tested positive for the influenza virus.
Conclusion: We found no case of influenza and SARS-CoV-2 co-infection among the patients studied. This suggests that the prevalence of influenza virus infection may be low in our setting and partly explains the relatively benign outcome of SARS-CoV-2 infections in our region.
References
2. Centers for Disease Control and Prevention.Key facts about influenza (flu) [cited December 2023]. Available from: https://www.cdc.gov/flu/about/keyfacts.htm
3. Institute of Medicine (US) Forum on Microbial Threats; Knobler SL, Mack A, Mahmoud A, et al. The Threat of Pandemic Influenza: Are We Ready? Workshop Summary. Washington (DC): National Academies Press (US); 2005. 1, The Story of Influenza [cited Dec 2023]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK22148/
4. Tong X, Xu X, Lv G, Wang H, Cheng A, Wang D, et al. Clinical characteristics and outcome of influenza virus infection among adults hospitalized with severe COVID-19: A retrospective cohort study from Wuhan, China. BMC Infect. Dis. 2021; 21: 341.
5. World Health Organization, Geneva 2020. WHO COVID-19 Dashboard [cited Dec 2021]. Available online: https://covid19.who.int/
6. Paget J, Staadegaard L, Wang X, Li Y, van Pomeren T, van Summeren J, et al. Global and national influenza-associated hospitalisation rates: Estimates for 40 countries and administrative regions. J. Glob. Health. 2023 Jan 27;13:04003.
7. Karlsson EA, Mook PAN, Vandemaele K, Fitzner J, Hammond A, Cozza V, et al. Review of global influenza circulation, late 2019 to 2020, and the impact of the COVID-19 pandemic on influenza circulation. Wkly. Epidemiol. Rec. 2021;96(25):241–264.
8. Nigeria Centre for Disease Control and Prevention. COVID-19 situation report. Bi-weekly epidemiological report 12. Epi-week 39–40: 26th September to 09th October 2022 [cited Nov 2022].Available from:https://ncdc.gov.ng/diseases/sitreps/?cat=14&name=An%20update%20of%20COVID-19%20outbreak%20in%20Nigeria
9. Dalhatu IT, Medina-Marino A, Olsen SJ, Hwang I, Gubio AB, Ekanem EE, et al. Influenza viruses in Nigeria, 2009-2010: Results from the first 17 months of a national influenza sentinel surveillance system. J. Infect. Dis. 2012;206 (Suppl 1): S121–S128.
10. Swets MC, Russell CD, Harrison EM, Docherty AB, Lone N, Girvan M, et al. SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses. Lancet. 2022; 399: 1463–1464.
11. Garg I, Gangu K, Shuja H, Agahi A, Sharma H, Bobba A, et al. COVID-19 and influenza coinfection outcomes among hospitalized patients in the United States: A propensity-matched analysis of national inpatient sample. Vaccines (Basel). 2022;10(12):2159.
12. Pourhoseingholi MA, Vahedi M, Rahimzadeh M. Sample size calculation in medical studies. Gastroenterol. Hepatol. Bed. Bench. 2013;6(1):14–17.
13. Naing L, Winn T, Rusli BN. Practical issues in calculating the sample size for prevalence studies. Arch. Orofac. Sci. 2006; 1.
14. Loeffelholz MJ, Alland D, Butler-Wu SM, Pandey U, Perno CF, Nava A, et al. Multicenter evaluation of the Cepheid Xpert Xpress SARS-CoV-2 test. J. Clin. Microbiol.2020;58:10.1128/jcm.00926-20.
15. World Health Organization. WHO R&D Blueprint for Epidemics Updating the WHO list of pathogens with epidemic and PHEIC potential [cited Dec 2023]. Available from: https://cdn.who.int/media/docs/default-source/blue-print/rd-blueprint_prioritization-2022_concept-note_v.1.pdf?sfvrsn=260e4e8f_3
16. Lingani M, Cissé A, Tialla D, Ilboudo AK, Savadogo M, Sawadogo C, et al. Coinfections with SARS-CoV-2 variants and influenza virus during the 2019 Coronavirus disease pandemic in Burkina Faso: A surveillance study. Health Sci. Rep. 2023; 6:e1041.
17. Dadashi M, Khaleghnejad S, Abedi Elkhichi PA, Goudarzi M, Goudarzi H, Taghavi A, et al. COVID-19 and influenza co-infection: A systematic review and meta-analysis. Front. Med. (Lausanne). 2021; 8: 681469.
18. Lagare A, Rajatonirina S, Testa J, Mamadou S. The epidemiology of seasonal influenza after the 2009 influenza pandemic in Africa: A systematic review. Afr.Health Sci. 2020; 20(4):1514–1536.
19. Dalhatu IT, Medina-Marino A, Olsen SJ, Hwang I, Gubio AB, Ekanem EE, et al. Influenza viruses in Nigeria, 2009–2010: results from the first 17 months of a national influenza sentinel surveillance system. J. Infect. Dis. 2012;206(Suppl 1):S121–S128.
20. Mmbaga VM, Mwasekaga MJ, Mmbuji P, Matonya M, Mwafulango A, Moshi S, et al. Results from the first 30 months of national sentinel surveillance for influenza in Tanzania, 2008–2010. J. Infect. Dis. 2012;206(Suppl 1):S80–S86.
21. Cardoso Y, Oliveira E, Vasconcelos J, Cohen AL, Francisco M. Characteristics of patients with influenza-like illness, severe acute respiratory illness, and laboratory-confirmed influenza at a major Children’s Hospital in Angola, 2009–2011. J. Infect. Dis. 2012;206(Suppl 1):S136–S139.
22. Manirakiza A, Ketta MB, Vickos U, Komoyo GF, Garba-Ouangole S, Bangue C, et al. Sentinel surveillance of influenza-like illness in the Central African Republic, 2010–2015. Arch Public Health. 2017;75:61
23. Tarnagda Z, Yougbaré I, Ilboudo AK, Kagoné T, Sanou AM, Cissé A, et al. Sentinel surveillance of influenza in Burkina Faso: identification of circulating strains during 2010–2012. Influenza Other Respir. Viruses. 2014;8:524–529.
24. Maïnassara HB, Lagare A, Tempia S, Sidiki A, Issaka B, Abdou Sidikou B, et al. Influenza sentinel surveillance among patients with influenza-like illness and severe acute respiratory illness within the framework of the National Reference Laboratory, Niger, 2009–2013. Plos One. 2015;10:e0133178.
25. Jones AH, Ampofo W, Akuffo R, Doman B, Duplessis C, Amankwa JA, et al. Sentinel surveillance for influenza among severe acute respiratory infection and acute febrile illness inpatients at three hospitals in Ghana. Influenza Other Respir. Viruses. 2016;10(5):367–374.
26. Sagripanti JL, Lytle CD. Inactivation of influenza virus by solar radiation. Photochem Photobiol. 2007;83:1278-1282.
27. Charland KM, Buckeridge DL, Sturtevant JL, Melton F, Reis BY, Mandl KD, et al. Effect of environmental factors on the spatio-temporal patterns of influenza spread. Epidemiol. Infect. 2009;137:1377-1387.
28. Centers for Disease Control and Prevention (CDC). The difference between flu and COVID-19 [cited Nov 2022]. Available from: https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm
29. Dhanasekaran V, Sullivan S, Edwards KM, Xie R, Khvorov A, Valkenburg SA, et al. Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination. Nat. Commun. 2022; 13:1721.
30. Yan X, Li K, Lei Z, Luo J, Wang Q, Wei S. Prevalence and associated outcomes of coinfection between SARS-CoV-2 and influenza: A systematic review and meta-analysis. Int. J. Infect. Dis. 2023;136:29–36.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This is an open-access journal and articles are distributed under the terms of the Creative Commons Attribution Non-Commercial Share-Alike License 4.0. This licence allows users to download and share, remix, tweak and build upon the article for non-commercial purposes, so long as the original authorship is acknowledged and the new creations are licensed under identical terms.
Nathan Yakubu Shehu, The West African Center for Emerging Infectious Diseases, Jos University Teaching Hospital, Jos, Plateau State, Nigeria
Department of Internal Medicine, Jos University Teaching Hospital, Jos, Plateau State, Nigeria
Mark Ojogba Okolo, Department of Microbiology, Jos University Teaching Hospital, Jos, Plateau State, Nigeria
Head of Department, Microbiology Department
Emmanuel Ameh Ameh, The West African Center for Emerging Infectious Diseases, Jos University Teaching Hospital, Jos, Plateau State, Nigeria
Department of Community Medicine, Jos University Teaching Hospital, Jos, Plateau State, Nigeria